Growth inhibitory effect of celecoxib and rofecoxib on human colorectal carcinoma cell lines

Anticancer Research

Volumn 25, Issue 1 A, 2005, Pages 225-233

  Buecher, Bruno ^a   Bouancheau, Delphine ^a   Broquet, Alexis ^a   Bezieau, Stéphane ^b   Denis, Marc G ^a   Bonnet, Christian ^a   Heymann, Marie Françoise ^a   Jarry, Anne ^a   Galmiche, Jean Paul ^a   Blottière, Hervé M ^a,c  

^a HÔTEL DIEU   (France)

^b UNIVERSITÉ DE NANTES   (France)

^c CEMAGREF   (France)

Author keywords

Colorectal cancer; COX 1; COX 2; NSAIDs; Proliferation

Indexed keywords

CELECOXIB; CRYSTAL VIOLET; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DNA; NONSTEROID ANTIINFLAMMATORY AGENT; ROFECOXIB;

ADENOCARCINOMA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CANCER PREVENTION; CARCINOGENESIS; CELL ASSAY; CELL PROLIFERATION; COLORECTAL CARCINOMA; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG SELECTIVITY; DRUG TARGETING; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

CACO-2 CELLS; CELL PROLIFERATION; COLORECTAL NEOPLASMS; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; HT29 CELLS; HUMANS; LACTONES; MEMBRANE PROTEINS; PHENOTYPE; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PYRAZOLES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SULFONAMIDES; SULFONES;

EID: 20144387785     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Dubois RN, Abramson SB, Crofford L, Gupta RA, Simon LS, Van De Putte LB and Lipsky PE: Cyclooxygenase in biology and disease. FASEB J 12: 1063-1073, 1998.
2. Chandrasekharan NV, Dai H, Roos KL, Evanson NK, Tomsik J, Elton TS and Simmons DL: COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proc Natl Acad Sci USA 99: 13926-13931, 2002.
3. Smith WL and Langenbach R: Why there are two cyclooxygenase isozymes. J Clin Invest 107: 1491-1495, 2001.
4. Smith WL, DeWitt DL and Garavito RM. Cyclooxygenases: structural, cellular, and molecular biology. Annu Rev Biochem 69: 145-182, 2000.
5. Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S and DuBois RN: Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 107: 1183-1188, 1994.
6. Sano H, Kawahito Y, Wilder RL, Hashiramoto A, Mukai S, Asai K, Kimura S, Kato H, Kondo M and Hla T: Expression of cyclooxygenase-1 and -2 in human colorectal cancer. Cancer Res 55: 3785-3789, 1995.
7. Karnes WE Jr, Shattuck-Brandt R, Burgart LJ, DuBois RN, Tester DJ, Cunningham JM, Kim CY, McDonnell SK, Schaid DJ and Thibodeau SN: Reduced COX-2 protein in colorectal cancer with defective mismatch repair. Cancer Res 58: 5473-5477, 1998.
8. Shao J, Sheng H, Aramandla R, Pereira MA, Lubet RA, Hawk E, Grogan L, Kirsch IR, Washington MK, Beauchamp RD and DuBois RN: Coordinate regulation of cyclooxygenase-2 and TGF-beta1 in replication error-positive colon cancer and azoxymethane-induced rat colonie tumors. Carcinogenesis 20: 185-191, 1999.
9. Boolbol SK, Dannenberg AJ, Chadburn A, Martucci C, Guo XJ, Ramonetti JT, Abreu-Goris M, Newmark HL, Lipkin ML, DeCosse JJ and Bertagnolli MM: Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis. Cancer Res 56: 2556-2560, 1996.
10. Rigas B, Goldman IS and Levine L: Altered eicosanoid levels in human colon cancer. J Lab Clin Med 122: 518-523, 1993.
11. Tsujii M and DuBois RN: Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 83: 493-501, 1995.
12. Liu CH, Chang SH, Narko K, Trifan OC, Wu MT, Smith E, Haudenschild C, Lane TF and Hla T: Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice. J Biol Chem 276: 18563-18569, 2001.
13. Buecher B, Heymann MF and Blottiere HM: Rationale and prospects for the use of cyclooxygenase-2 (COX-2) inhibitors in colorectal cancer. Gastroenterol. Clin Biol 25: 967-978, 2001.
14. Paganini-Hill A, Hsu G, Ross RK and Henderson BE: Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 326: 1290-1291, 1992.
15. DuBois RN, Giardiello FM and Smalley WE: Nonsteroidal anti-inflammatory drugs, eicosanoids, and colorectal cancer prevention. Gastroenterol Clin North Am 25: 773-791, 1996.
16. Sandler RS, Galanko JC, Murray SC, Helm JF and Woosley JT: Aspirin and nonsteroidal anti-inflammatory agents and risk for colorectal adenomas. Gastroenterology 114: 441-447, 1998.
17. Debinski HS, Trojan J, Nugent KP, Spigelman AD and Phillips RK: Effect of sulindac on small polyps in familial adenomatous polyposis. Lancet 345: 855-856, 1995.
18. Steinbach G, Lynch PM, Phillips RK, Wallace MH, Hawk E, Gordon GB, Wakabayashi N, Saunders B, Shen Y, Fujimura T, Su LK and Levin B: The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 342: 1946-1952, 2000.
19. Giardiello FM, Yang VW, Hylind LM, Krush AJ, Petersen GM, Trimbath JD, Piantadosi S, Garrett E, Geiman DE, Hubbard W, Offerhaus GJA and Hamilton SR: Primary chemoprevention of familial adenomatous polyposis with sulindac. N Engl J Med 346: 1054-1059, 2002.
20. Cruz-Correa M, Hylind LM, Romans KE, Booker SV and Giardiello FM: Long term treatment with sulindac in familial adenomatous polyposis: a prospective cohort study. Gastroenterology 122: 641-645, 2002.
21. Zhang X, Morham SG, Langenbach R and Young DA: Malignant transformation and antineoplastic actions of nonsteroidal antiinflammatory drugs (NSAIDs) on cyclooxygenase-null embryo fibroblasts. J Exp Med 190: 451-459, 1999.
22. Song X, Lin HP, Johnson AJ, Tseng PH, Yang YT, Kulp SK and Chen CS: Cyclooxygenase-2, player or spectator in cyclooxygenase-2 inhibitor-induced apoptosis in prostate cancer cells. J Natl Cancer Inst 94: 585-5891, 2002.
23. Shiff SJ, Qiao L, Tsai LL and Rigas B: Sulindac sulfide, an aspirin-like compound, inhibits proliferation, causes cell cycle quiescence, and induces apoptosis in HT-29 colon adenocarcinoma cells. J Clin Invest 96: 491-503, 1995.
24. Elder DJ, Halton DE, Crew TE and Paraskeva C: Apoptosis induction and cyclooxygenase-2 regulation in human colorectal adenoma and carcinoma cell lines by the cyclooxygenase-2-selective non-steroidal anti-inflammatory drug NS-398. Int J Cancer 86: 553-560, 2000.
25. Zhang Z and DuBois RN: Par-4, a proapoptotic gene, is regulated by NSAIDs in human colon carcinoma cells. Gastroenterology 118: 1012-1017, 2000.
26. Gupta RA and DuBois RN: Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nature Rev Cancer 1: 11-21, 2001.
27. Blottiere HM, Zennadi R, Gregoire M, Aillet G, Denis MG, Meflah K and Le Pendu J: Analysis of the relationship between stage of differentiation and NK/LAK susceptibility of colon carcinoma cells. Int J Cancer 53: 409-417, 1993.
28. Siavoshian S, Segain JP, Kornprobst M, Bonnet C, Cherbut C, Galmiche JP and Blottiere HM: Butyrate and trichostatin A effects on the proliferation/differentiation of human intestinal epithelial cells: induction of cyclin D3 and p21 expression. Gut 46: 507-514, 2000.
29. Parsons R, Myeroff LL, Liu B, Willson JK, Markowitz SD, Kinzler KW and Vogelstein B: Microsatellite instability and mutations of the transforming growth factor beta type II receptor gene in colorectal cancer. Cancer Res 55: 5548-5550, 1995.
30. Hoang JM, Cottu PH, Thuille B, Salmon RJ, Thomas G and Hamelin R: BAT-26, an indicator of the replication error phenotype in colorectal cancers and cell lines. Cancer Res 57: 300-303, 1997.
31. Boudreau MD, Sohn KH, Rhee SH, Lee SW, Hunt JD and Hwang DH: Suppression of tumor cell growth both in nude mice and in culture by n-3 polyunsaturated fatty acids: mediation through cyclooxygenase-independent pathways. Cancer Res 61: 1386-1391, 2001.
32. Sheng H, Shao J, Kirkland SC, Isakson P, Coffey RJ, Morrow J, Beauchamp RD and DuBois RN: Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2. J Clin Invest 99: 2254-2259, 1997.
33. Hsi LC, Baek SJ and Eling TE: Lack of cyclooxygenase-2 activity in HT-29 human colorectal carcinoma cells. Exp Cell Res 256: 563-5670, 2000.
34. Masferrer JL, Leahy KM, Koki AT, Zweifel BS, Settle SL, Woerner BM, Edwards DA, Flickinger AG, Moore RJ and Seibert K: Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 60: 1306-1311, 2000.
35. Boland CR, Thibodeau SN, Hamilton SR, Sidransky D, Eshleman JR, Burt RW, Meltzer SJ, Rodriguez-Bigas MA, Fodde R, Ranzani GN and Srivastava S: A National Cancer Institute Workshop on microsatellite instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 58: 5248-5257, 1998.
36. Warner TD, Giuliano F, Vojnovic I, Bukasa A, Mitchell JA and Vane JR: Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci USA 96: 7563-7568, 1999.
37. Chan CC, Boyce S, Brideau C, Charleson S, Cromlish W, Ethier D, Evans J, Ford-Hutchinson AW, Forrest MJ, Gauthier JY, Gordon R, Gresser M et al: Rofecoxib [Vioxx, MK-0966; 4-(4′-methylsulfonylphenyl)-3-phenyl-2-(5H)- furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles. J Pharmacol Exp Ther 290: 551-560, 1999.
38. Waskewich C, Blumenthal RD, Li H, Stein R, Goldenberg DM and Burton J: Celecoxib exhibits the greatest potency amongst cyclooxygenase (COX) inhibitors for growth inhibition of COX-2-negative hematopoietic and epithelial cell lines. Cancer Res 62: 2029-2033, 2002.
39. Yamazaki R, Kusunoki N, Matsuzaki T, Hashimoto S and Kawai S: Selective cyclooxygenase-2 inhibitors show a diiferential ability to inhibit proliferation and induce apoptosis of colon adenocarcinoma cells. FEBS Lett 531: 278-284, 2002.
40. Zhu J, Song X, Lin HP, Young DC, Yan S, Marquez VE and Chen CS: Using cyclooxygenase-2 inhibitors as molecular platforms to develop a new class of apoptosis-inducing agents. J Natl Cancer Inst 94: 1745-1757, 2002.
41. Arico S, Pattingre S, Bauvy C, Gane P, Barbat A, Codogno P and Ogier-Denis E: Celecoxib induces apoptosis by inhibiting 3-phosphoinositide- dependent protein kinase-1 activity in the human colon cancer HT-29 cell line. J Biol Chem 277: 27613-27621, 2002.
42. Grösch S, Tegeder I, Niederberger E, Bräutigam L and Geisslinger G: COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib. FASEB J 15: 2742-2754, 2001.
43. Chulada PC, Thompson MB, Mahler JF, Doyle CM, Gaul BW, Lee C et al: Genetic disruption of ptgs-1, as well as ptgs-2, reduces intestinal tumorigenesis in Min mice. Cancer Res 60: 4705-4708, 2000.
44. Yao M, Kargman S, Lam EC, Kelly CR, Zheng Y, Luk P, Kwong E, Evans JF and Wolfe MM: Inhibition of cyclooxygenase-2 by rofecoxib attenuates the growth and metastatic potential of colorectal carcinoma in mice. Cancer Res 63: 586-592, 2003.